Optimum at 1 receptor-neprilysin inhibition has superior cardioprotective effects compared with at 1 receptor blockade alone in hypertensive rats

Kidney International

Volumn 88, Issue 1, 2015, Pages 109-120

  Roksnoer, Lodi C W ^a   Van Veghel, Richard ^a   De Vries, René ^a   Garrelds, Ingrid M ^a   Bhaggoe, Usha M ^a   Friesema, Edith C H ^a   Leijten, Frank P J ^a   Poglitsch, Marko ^b   Domenig, Oliver ^b   Clahsen Van Groningen, Marian C ^a   Hoorn, Ewout J ^a   Danser, A H Jan ^a   Batenburg, Wendy W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

AT1 receptor antagonist; Cardiac hypertrophy; Hypertension; Neprilysin inhibition; Renin; Sodium hydrogen exchanger 3

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ATRIAL NATRIURETIC FACTOR; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; IRBESARTAN; MEMBRANE METALLOENDOPEPTIDASE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; SODIUM PROTON EXCHANGE PROTEIN 3; THIORPHAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC PEPTIDE, RAT; BIPHENYL DERIVATIVE; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; OLIGOPEPTIDE; PIPERIDINE DERIVATIVE; PROTEINASE INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER 3; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; ENZYME INHIBITION; FLUID INTAKE; HEART PROTECTION; HETEROZYGOSITY; HOMOZYGOSITY; HYPERTENSION; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TANDEM MASS SPECTROMETRY; UPREGULATION; URINE VOLUME; VASOCONSTRICTION; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERIAL PRESSURE; BLOOD; BODY WEIGHT; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; COMPARATIVE STUDY; DRUG EFFECTS; KIDNEY; METABOLISM; ORGAN SIZE; PATHOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ARTERIAL PRESSURE; ATRIAL NATRIURETIC FACTOR; BIPHENYL COMPOUNDS; BODY WEIGHT; ENDOTHELIN B RECEPTOR ANTAGONISTS; ENDOTHELIN-1; KIDNEY; MYOCARDIUM; MYOCYTES, CARDIAC; NEPRILYSIN; OLIGOPEPTIDES; ORGAN SIZE; PIPERIDINES; PROTEASE INHIBITORS; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN B; RENIN-ANGIOTENSIN SYSTEM; SODIUM-HYDROGEN ANTIPORTER; TETRAZOLES; THIORPHAN; UP-REGULATION; VASOCONSTRICTION; VASODILATION;

EID: 84934437930     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.107     Document Type: Article

References (52)

1. de Boer RA, Azizi M, Danser AHJ et al. Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. J Renin Angiotensin Aldosterone Syst 2012; 13: 409-412.
2. Seymour AA, Norman JA, Asaad MM et al. Antihypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidase. J Cardiovasc Pharmacol 1991; 17: 296-304.
3. von Lueder TG, Sangaralingham SJ, Wang BH et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013; 6: 594-605.
4. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998; 97: 2323-2330.
5. Ando S, Rahman MA, Butler GC et al. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995; 26: 1160-1166.
6. McClean DR, Ikram H, Garlick AH et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 479-486.
7. Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356: 615-620.
8. Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17: 103-111.
9. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000; 356: 608-609.
10. Ruilope LM, Dukat A, Bohm M et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375: 1255-1266.
11. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
12. Pu Q, Brassard P, Javeshghani DM et al. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens 2008; 26: 322-333.
13. Donowitz M, Li X. Regulatory binding partners and complexes of NHE3. Physiol Rev 2007; 87: 825-872.
14. Bugaj V, Pochynyuk O, Mironova E et al. Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct. Am J Physiol Renal Physiol 2008; 295: F1063-F1070.
15. Higa T, Horinouchi T, Aoyagi H et al. Endothelin type B receptor-induced sustained Ca2+ influx involves G(q/11)/phospholipase C-independent, p38 mitogen-activated protein kinase-dependent activation of Na+/H+ exchanger. J Pharmacol Sci 2010; 113: 276-280.
16. Eberlin M, Muck T, Michel MC. A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. Front Pharmacol 2012; 3: 93.
17. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 344: 541-544.
18. Bachmann S, Peters J, Engler E et al. Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model. Kidney Int 1992; 41: 24-36.
19. Stasch JP, Hirth-Dietrich C, Ganten D, Wegner M. Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens 1996; 9: 795-802.
20. Wong KR, Xie MH, Shi LB et al. Urinary cGMP as biological marker of the renal activity of atrial natriuretic factor. Am J Physiol 1988; 255: F1220-F1224.
21. van Esch JHM, Gembardt F, Sterner-Kock A et al. Cardiac phenotype and angiotensin II levels in AT1a, AT1b and AT2 receptor single, double and triple knockouts. Cardiovasc Res 2010; 86: 401-409.
22. Kobayashi T, Miyauchi T, Sakai S et al. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol 1999; 276: H1197-H1206.
23. Peng Y, Amemiya M, Yang X et al. ET(B) receptor activation causes exocytic insertion of NHE3 in OKP cells. Am J Physiol Renal Physiol 2001; 280: F34-F42.
24. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003; 41: 383-389.
25. Irvine JC, Ganthavee V, Love JE et al. The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy. PLoS One 2012; 7: e44481.
26. Packer M, McMurray JJ, Desai AS et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131: 54-61.
27. Franco V, Chen YF, Oparil S et al. Atrial natriuretic peptide dosedependently inhibits pressure overload-induced cardiac remodeling. Hypertension 2004; 44: 746-750.
28. Mori T, Chen YF, Feng JA et al. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res 2004; 61: 771-779.
29. Pandya K, Smithies O. beta-MyHC and cardiac hypertrophy: size does matter. Circ Res 2011; 109: 609-610.
30. Rubattu S, Sciarretta S, Valenti V et al. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21: 733-741.
31. Henrich WL, McAllister EA, Smith PB, Campbell WB. Guanosine 3',5'-cyclic monophosphate as a mediator of inhibition of renin release. Am J Physiol 1988; 255: F474-F478.
32. Mironova E, Bugaj V, Roos KP et al. Aldosterone-independent regulation of the epithelial Na+ channel (ENaC) by vasopressin in adrenalectomized mice. Proc Natl Acad Sci USA 2012; 109: 10095-10100.
33. Gurley SB, Riquier-Brison AD, Schnermann J et al. AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab 2011; 13: 469-475.
34. Arroyo JP, Lagnaz D, Ronzaud C et al. Nedd4-2 modulates renal Na+-Cl? cotransporter via the aldosterone-SGK1-Nedd4-2 pathway. J Am Soc Nephrol 2011; 22: 1707-1719.
35. Miura H, Liu Y, Gutterman DD. Human coronary arteriolar dilation to bradykinin depends on membrane hyperpolarization: contribution of nitric oxide and Ca2+-activated K+ channels. Circulation 1999; 99: 3132-3138.
36. Batenburg WW, Popp R, Fleming I et al. Bradykinin-induced relaxation of coronary microarteries: S-nitrosothiols as EDHF? Br J Pharmacol 2004; 142: 125-135.
37. Bellien J, Iacob M, Eltchaninoff H et al. AT1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NOS inhibition in humans. Clin Sci (Lond) 2007; 112: 393-401.
38. Goto K, Fujii K, Kansui Y, Iida M. Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors. Clin Exp Pharmacol Physiol 2004; 31: 650-655.
39. Skovsted GF, Kruse LS, Larsen R et al. Heart ischaemia-reperfusion induces local up-regulation of vasoconstrictor endothelin ETB receptors in rat coronary arteries downstream of occlusion. Br J Pharmacol 2014; 171: 2726-2738.
40. Moltzer E, Verkuil AV, van Veghel R et al. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension 2010; 55: 516-522.
41. You D, Loufrani L, Baron C et al. High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats. Circulation 2005; 111: 1006-1011.
42. Balcarek J, Seva Pessoa B, Bryson C et al. Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition. Hypertension 2014; 63: 942-950.
43. Demerath T, Staffel J, Schreiber A et al. Natriuretic peptides buffer renindependent hypertension. Am J Physiol Renal Physiol 2014; 306: F1489-F1498.
44. van Esch JHM, Moltzer E, van Veghel R et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens 2010; 28: 2145-2155.
45. Danser AHJ, van Kats JP, Admiraal PJJ et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24: 37-48.
46. de Lannoy LM, Danser AHJ, van Kats JP et al. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 1997; 29: 1240-1251.
47. Kovarik JJ, Antlanger M, Domenig O et al. Molecular regulation of the renin-angiotensin system in haemodialysis patients. Nephrol Dial Transplant 2015; 30: 115-123.
48. Leemans JC, Stokman G, Claessen N et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115: 2894-2903.
49. van der Lubbe N, Moes AD, Rosenbaek LL et al. K+-induced natriuresis is preserved during Na+ depletion and accompanied by inhibition of the Na+-Cl? cotransporter. Am J Physiol Renal Physiol 2013; 305: F1177-F1188.
50. Lu X, Krop M, Batenburg WW et al. Renin inhibitor VTP-27999 differs from aliskiren: focus on their intracellular accumulation and the (pro)renin receptor. J Hypertens 2014; 32: 1255-1263.
51. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977; 41: 19-26.
52. MaassenVanDenBrink A, de Vries R, Saxena PR et al. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res 1999; 44: 407-415.